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b-glucosidases inhibitionAbstract Cu (I)-catalyzed alkyne–azide cycloaddition was carried out for the preparation of novel
1,4-disubstituted 1,2,3-triazoles of D-(+)-pinitol. All the analogs were screened for cytotoxicity
against promyelocytic leukemia (HL-60), colorectal carcinoma (HCT 116) and pancreatic
carcinoma (Mia-Paca-2) cancer cell lines using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) cytotoxicity assay. Compounds 2, 3 and 7 showed the best activity with IC50 of
19.2, 17.5 and 16.4 lM against leukemia (HL-60), colorectal carcinoma (HCT 116) and pancreatic
carcinoma (Mia-Paca-2) cell lines respectively. All the triazolyl analogs were further evaluated for
b-glucosidase inhibitory activity, wherein, the deprotected derivatives: 6a, 18a and 25a showed
better activity with IC50 of 148.5, 139.2 and 142.4 lM respectively. The structure activity relation-
ship (SAR) studies revealed that the analogs with bromo, nitro or methyl groups in R (substituted
phenyl moiety attached to 1,2,3-triazole) moiety exhibited better cytotoxicity, while as, the analogs
with N-substituted long chain aliphatic hydrocarbon R moieties displayed effective b-glucosidase
inhibition.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
D-(+)-pinitol (3-O-methyl-D-chiro-inositol) is a methylated
derivative of D-chiro-inositol and is a prominent component
of dietary legumes such as soybeans (Davis et al., 2000).
Recently, we have isolated this compound from the aerial parts
of Rhododendron lepidotum in appreciable yields (Rehman
et al., 2013). In mammalian cells, D-(+)-pinitol is actively
converted to D-chiro-inositol, an optically active epimer of
myo-inositol (Kaneko, 1991). D-chiro-inositol is a putative
insulin-like mediator and exerts its effects by stimulating)-pinitol.
2 Shakeel-u-Rehman et al.glucose transport and modulating the activities of hepatic key
carbohydrate metabolizing enzymes (Asplin et al., 1993; Dang
et al., 2010; Bhat et al., 2009). Additionally, this compound has
been reported to possess potential anti-inflammatory activity
by modulating the Th1/Th2 response, NF-jB signaling or
proinflammatory cytokine expression (Lee et al., 2007; Sethi
et al., 2008; Sivakumar et al., 2010; Singh et al., 2001).
In experimental animal models of inflammation, pinitol has
been shown to be effective against carrageenan-induced paw
edema (Kim et al., 2005) and ovalbumin-induced airway
inflammation in a murine model of asthma (Pitt et al., 2013).
It has been reported that D-(+)-pinitol has the potential to
treat Alzheimer’s disease by protecting CNS synapse against
Ab oligomers through their insulin mimetic activity. Its deoxy
nucleobase derivatives exhibit potential antiviral activity
against HIV-1, HSV-1 and HSV-2 viruses and antitumour
activity against lung (PG cell) and bladder (T-24) cancer cell
lines (Zhan et al., 2006). The triazole and benzotriazole
analogs of D-(+)-pinitol have been found to exhibit significant
antitumor activity against lung (PG) cancer cell line with EC50
of 11.3 and 22.6 lM respectively (Zhan and Lou, 2007).
Recent studies have shown potential anti-metastatic efficacy
of D-(+)-pinitol against the migration and the invasion of
human prostate cancer cells (Lin et al., 2013). Pinitol deriva-
tives have been reported to exhibit b-glucosidase inhibitory
activities (Falshaw et al., 2000), thus adding to their biological
importance, since glycosidase inhibitors are the potential
therapeutic agents (Dwek et al., 2002).
Click chemistry of natural products has acquired great rep-
utation in recent years for the development of bioactive natu-
ral product analogs. Some of the molecules studied include
alkaloids (Baraniak et al., 2011), coumarins (Olomola et al.,
2013; Rehman et al., 2014; Farooq et al., 2014), saponins
(Perez-Labrada et al., 2011), steroids (Suh et al., 2004) and ter-
penoids (Vasilevsky et al., 2011; Lone et al., 2014). Triazoles
have attracted considerable attention from organic and medic-
inal chemists due to their considerable biological activities such
as anticancer (Zhou and Wang, 2012; Kumar et al., 2011), glu-
cosidase inhibitory (Rossi and Basu, 2005; Ferreira et al.,
2010), immunosuppressant (Chinthakindi et al., 2013), antivi-
ral, antimicrobial, anticonvulsant, and anti-inflammatory
activities (Wamhoff, 1984). Triazole based compounds such
as anastrozole, letrozole and vorozole are very important anti-
neoplastic drugs, while as, radicicol triazole, indolyl-
substituted triazole of novobiocin, lavendustin triazole and
combretastatin triazoles are promising anticancer agents
(Zhou and Wang, 2012). Inspired by this, a large number of
triazole based compounds have been exploited as anticancer
drugs/leads in recent years (Zhou and Wang, 2012). In addi-
tion to this, glycosyl 1,2,3-triazoles and many triazole-
derived carbohydrates have been found to be excellent glycosi-
dase inhibitors (Rossi and Basu, 2005; Ferreira et al., 2010).
Thus, the design and synthesis of novel triazole derivatives is
the prospective direction for the development of novel glucosi-
dase inhibitors and anticancer agents with better curative
effect, lower toxicity as well as higher selectivity.
Thus, based on the reported anticancer and b-glucosidase
inhibitory activities of D-(+)-pinitol as well as triazole based
scaffolds, we designed and synthesized a library of triazolyl
derivatives of D-(+)-pinitol for improved cytotoxic andPlease cite this article in press as: Shakeel-u-Rehman, et al., Click chemistry inspire
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ture activity relationship (SAR).2. Results and discussion
2.1. Chemistry
In view of the interesting pharmacological activities of inositol
derivatives in general and D-(+)-pinitol in particular, a click
chemistry inspired approach involving copper(I)-catalyzed
union of terminal alkynes with organic azides has been
exploited for the synthesis of novel 1,4-disubstituted 1,2,3-
triazolyl derivatives of D-(+)-pinitol in excellent yields. The
copper(I)-catalyzed click chemistry procedure (Huisgen 3 + 2
cycloaddition) is the best click reaction (Kolb and Sharpless,
2003) known to date and exhibits remarkably broad scope
and exquisite selectivity and has contrasting applications in
chemistry, biology, and materials science. It has enabled
demanding synthesis of novel biologically active compounds
and materials (Wu et al., 2004). Terminal alkynes and organic
azides containing a wide range of functional groups are
regiospecifically united to form the corresponding triazole
products in excellent yields.
In the present study, D-(+)-pinitol was taken as starting
material and protected at syn-1,2 (aa) and syn-5,6-hydroxyl
(bb) positions using 2,2-dimethoxypropane in presence of
para-toluene sulfonic acid (p-TSA) in acetone to form its
diacetonide (SR-A) (Scheme 1). Since these two pairs of hydro-
xyl groups (1,2 and 5,6) are in same orientation, it becomes
easy to protect them leaving only one hydroxyl group free.
The structure of SR-A was determined by spectral data analy-
sis (1H and 13C NMR) and HR-ESIMS (m/z 275.1488). Proton
singlets at d 1.51 ppm and 1.37 ppm (integrating for six
protons each) were assigned to protons of four methyl groups.
The other d values were almost similar as that of the parent
molecule. SR-A was further alkylated at the only hydroxyl
(C-3) position using propargyl bromide and NaH (base) in
acetonitrile to form its propargylated product (SR-B). Proton
singlets (apparent) at d 2.45 ppm and 4.24 ppm (integrating for
one and two protons respectively) represent terminal alkyne
proton and two methylenic protons respectively. The other
proton signals along with 13C NMR and HR-ESIMS
(313.1632) data confirmed the structure of SR-B.
Using SR-B as a key template, it was subjected to 1,3-
dipolar cycloaddition reaction typically called Huisgen
cycloaddition with various freshly prepared organic azides
under Sharpless click chemistry conditions [CuSO4_s5H2O and
sodium ascorbate in t-BuOH:H2O (1:1)] to afford regioselec-
tively 1,4-disubstituted 1,2,3-triazole products (1–25) in good
to excellent yields (Scheme 1). Under click conditions a series
of such analogs was prepared to look for structure–activity
relationship. The structures of all the synthesized triazolyl
derivatives were established by analytical and spectral data
analysis. Formation of products was unambiguously confirmed
by a downfield H-5 proton singlet (almost around 8.0 ppm) and
other proton resonances in the aromatic region. Further char-
acterization of all the products was done using 13C NMR-
DEPT and HR-ESIMS data. These derivatives were further
treated with TFA:H2O (1:1) to yield respective deprotectedd facile synthesis and bioevaluation of novel triazolyl analogs of D-(+)-pinitol.
Scheme 1 Preparation of triazolyl derivatives of D-(+)-pinitol using Cu-(I)-catalyzed Huisgen 1,3-dipolar cycloaddition.
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4 Shakeel-u-Rehman et al.analogs (1a–25a) in appreciable yields. Formation of products
was confirmed by the disappearance of methyl signals
(d 1.3–1.6 ppm) in their 1H NMR spectra.
2.2. Biology
2.2.1. In vitro screening of the novel analogs against human
cancer cell lines
As part of our ongoing research program on bio-prospection of
natural products (Rehman et al., 2015; Lone et al., 2013a,b), all
the newly synthesized analogs (1/1a–25/25a) prepared through
click reaction were screened for anti-proliferative activity
against promyelocytic leukemia (HL-60), colorectal carcinoma
(HCT-116) and pancreatic carcinoma (Mia-Paca-2) cell lines
using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo
liumbromide] assay.
Preliminary cytotoxicity screening of the analogs was
carried out at 100 lM concentration and cytotoxicity was
determined. Some of the synthesized analogs displayed broad
spectrum cytotoxic effect in a dose dependent manner. The
analogs that exhibited greater than 50% anti-proliferative
activity at 100 lM concentration were further assayed at
different concentrations (10–100 lM) to determine the IC50
values (Table 1). The values are the average of triplicate anal-
ysis. BEZ-235 (Dactolisib), an imidazoquinoline derivative,
used as a potent antineoplastic agent was used as positive
control in this assay.
Of the synthesized triazoles, only seven derivatives exhibited
appreciable anti-proliferative activity against the tested cancer
cell lines. Compounds 2, 3 and 7 showed comparatively better
activity with IC50 values of 19.2, 17.5 and 16.4 lM against
leukemia (HL-60), colorectal carcinoma (HCT-116) and
pancreatic carcinoma (Mia-Paca-2) cell lines respectively.
Compound 22 displayed selective cytotoxicity against colorec-
tal carcinoma (HCT-116) cell line with IC50 of 24.8 lM.Among
all the synthesized derivatives a few showed moderate activity,
while as, others were weakly active toward the tested cancer cell
lines. In addition to this, oxygen deprotected analogs (1a–25a)
were unable to sensitize any of the tested cancer cell line.Table 1 IC50 (lM) values of D-(+)-pinitol derived triazoles
against promyelocytic leukemia (HL-60), colorectal carcinoma
(HCT 116) and pancreatic carcinoma (Mia-Paca-2) cell lines
using MTT assay.
S.
no.
Entry HL-60
(IC50)
HCT-116
(IC50)
Mia-Paca-2
(IC50)
1 SR-A 46.4 ± 0.98 38.3 ± 0.58 >100 lM
2 2 19.2 ± 0.48 20.5 ± 0.45 26.3 ± 0.25
3 3 22.2 ± 0.82 17.5 ± 0.38 24.7 ± 0.54
4 4 >100 lM 30.3 ± 0.62 42.2 ± 0.34
5 7 25.3 ± 0.22 37.3 ± 0.52 16.4 ± 0.28
6 8 33.7 ± 0.37 31.6 ± 0.35 23.9 ± 022
7 22 >100 lM 24.8 ± 0.38 >100 lM
8 24 42.0 ± 0.50 32.4 ± 0.48 25.5 ± 0.20
9 BEZ-
235
12.44
± 0.26
0.048 ± 0.005 1.24 ± 0.03
>100 lM: These compounds (along with the other synthesized
derivatives not mentioned in the table) did not pass the preliminary
screening against the tested cancer cells.
BEZ-235 was used as positive control.
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tionship (SAR) was drawn which reflects that the compounds
with bromo substitution in R moiety (2 and 4) are compara-
tively effective cytotoxic agents. Compound 3 with a 2,5-
dimethylphenyl R moiety displayed significant cytotoxicity
against all the tested cancer cells, while as, compound 17 with
a 5-iodo-2-methylphenyl R moiety was ineffective to sensitize
any of the cancer cell line in the preliminary cytotoxicity test-
ing, highlighting the beneficial impact of an extra methyl group
at 5 position in SR-3 toward the cytotoxic activity. However, it
was also observed that a nitro (NO2) functionality at ortho and
meta position in the R moiety (8 and 24) of pinitol triazoles
plays a significant role in achieving better and enhanced activ-
ity against all the tested cancer cell lines, while as, compound 5
having para nitro functionality in the R moiety is inactive
toward the tested cancer cell lines. Compound 22 bearing an
orthocyanophenyl R moiety exhibited selective cytotoxic
activity against HCT-116 cell line, while as, paracyanophenyl
analog (6) did not pass the preliminary cytotoxicity testing.
2.2.2. Glucosidase inhibition studies
Glycosidases are carbohydrate processing enzymes which are
implicated in an array of vital biological processes that include
cell–cell and cell-virus recognition, synthesis of complex carbo-
hydrates, N-linked glycoprotein processing (Gloster and
Vocadlo, 2012; Horne et al., 2011). Inhibitors of such enzymes,
both natural and synthetic, have been the subject of extensive
studies in the past few decades. Such inhibitors have been
found to have tremendous potential as therapeutic agents in
the treatment of a number of diseases such as diabetes, obesity,
high blood pressure, viral infection, lysosomal storage disor-
der, and tumor metastasis (Dedola et al., 2010; Sa´nchez-
Medina et al., 2001; Mehta et al., 1998; Yoon et al., 1978;
Simoes-Pires et al., 2009; Verma et al., 2012). There is no
doubt that many more glycosidase inhibitors of practical use
remain to be discovered. In view of the early reports of
b-glucosidase inhibition by pinitol derivatives (Falshaw
et al., 2000) and certain carbohydrate derived triazoles
(Kumar et al., 2011) and the necessity to develop new glycosi-
dase inhibitors, the present work was aimed to evaluate the
possible b-glucosidase inhibitory activity of the triazolyl
derivatives of D-(+)-pinitol.Table 2 IC50 (lM) values of D-(+)-pinitol derived triazoles
a
against sweet almond b-glucosidase.
S. no. Entry IC50
1 6a 148.5 ± 1.21
2 8a 169.3 ± 2.08
3 12a 188.6 ± 2.23
4 13a 172.8 ± 1.79
5 15a 202.6 ± 1.85
6 18a 139.2 ± 1.55
7 22a 186.3 ± 1.39
8 23a 208.9 ± 1.88
9 24a 216.8 ± 2.29
10 25a 142.4 ± 1.88
11 Castanospermine 108.6 ± 1.12
a The compounds that are not mentioned in the table did not pass
the preliminary screening.
d facile synthesis and bioevaluation of novel triazolyl analogs of D-(+)-pinitol.
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166.7 lM concentration and percent glucosidase inhibition
was determined. The inhibitory effects of all the synthesized
derivatives were compared with those of castanospermine, a
well-known and potent b-glycosidase inhibitor (Saul et al.,
1983). The analogs that exhibited significant b-glucosidase
inhibition (>50%) at the preliminary screening concentration
were further assayed at different concentrations (16.6, 41.5,
83.3, 166.7 and 250.0 lM) to generate the IC50 values (Table 2).
The values are the average of triplicate analysis.
Of the synthesized analogs, only ten exhibited appreciable
enzyme inhibition against the sweet almond b-glucosidase.
Compounds 6a, 18a and 25a showed the best activity with
IC50 of 148.5, 139.2 and 142.4 lM respectively, while as major-
ity of the derivatives were weakly active against the tested
enzyme. The activity profile (Table 2), reflects that the com-
pounds with –NO2 or –CN substitutions in R-moiety display
strong b-glucosidase inhibitory effects. Compounds 6a, 22a
and 23a with –CN functionality at p, o and m positions in R
moiety displayed strong inhibitory effects with IC50 of 148.5,
186.3 and 208.9 lM respectively. Similarly, 8a, 24a and 25a
with –NO2 group at o, m and p positions in R moiety also
showed satisfactory b-glucosidase inhibition with IC50 of
169.3, 216.8 and 142.4 lM respectively. These observations
reveal that the analogs with p-CN and p-NO2 substitutions
in R moiety are more active than the corresponding ortho
and meta substituted derivatives. Additionally, Compounds
12a, 13a and 15a with nitrogen in R moieties displayed signif-
icant b-glucosidase inhibition. However, 18a with n-octyl R
moiety showed strong b-glucosidase inhibition with IC50 of
139.2 lM highlighting the importance of aliphatic hydrocar-
bon chain for achieving the better and enhanced inhibitory
activity. Hence, these results suggest that N-containing R moi-
eties along with long chain aliphatic hydrocarbon R moieties
seem to be essential for b-glucosidase inhibition. Based on
the notable b-glucosidase inhibitory activity of triazolyl deriva-
tives of D-(+)-pinitol, it would not be surprising that such
molecules could become the center of attraction for the medic-
inal chemists working in this field.
It is noteworthy to mention that it is not only the effect of a
particular group but also its position plays a significant role in
bioactivity. The most active compounds could become a better
arsenal toward the corresponding sensitive cell lines or
enzymes after further polishing and fine tuning.3. Conclusion
A diverse series of novel triazolyl analogs of D-(+)-pinitol was
prepared and evaluated for cytotoxic and b-glucosidase inhibi-
tory activities. The most potent cytotoxic activity was observed
in those analogs where R moiety was substituted with bromo
(2 and 4), nitro (8 and 24) or dimethyl (3) functionality.
Among the tested cell lines, colorectal carcinoma (HCT 116)
cell line was sensitive toward most of the synthesized
derivatives. These triazolyl derivatives along with their
corresponding deprotected analogs were further screened for
b-glucosidase inhibitory activity, wherein, interestingly only
hydroxyl deprotected derivatives showed appreciable results
for glucosidase inhibition. N-containing R moieties along
with long chain aliphatic hydrocarbon R moieties seem to
be crucial for b-glucosidase inhibition. Additionally, thePlease cite this article in press as: Shakeel-u-Rehman, et al., Click chemistry inspire
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activity against a particular target also depend on the nature
and position of the functional group/substituent attached to
R moiety of these triazoles. Systematic change of position of
these functionalities might be of interest to optimize pinitol
triazoles against the targets of therapeutic relevance.4. Experimental
4.1. Chemistry
All reagents for chemical synthesis were obtained from Sigma
Aldrich and the solvents used in reactions were distilled and
dried prior to use. Reactions were carried out in Branson
sonicator-3510. All the chemical reactions were monitored by
TLC on 0.25 mm silica gel 60 F254 plates (E. Merck) and the
spots were visualized at 366 and 254 nm in a UV chamber.
Purification of compounds was carried out by column
chromatography using Silica gel 60–120 mesh stationary
phase. 1H NMR and 13C NMR spectra (with chemical shifts
expressed in ppm and coupling constants in Hertz) were
recorded on Bruker DPX 200, 400 and DPX 500 instruments
using CDCl3 as the solvent with TMS as internal standard.
High resolution mass spectra (HRMS) were recorded on
Agilent Technologies 6540 instrument and melting points of
compounds were recorded on Buchi melting point apparatus
B-542.
4.1.1. Preparation of 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-
D-chiro-inositol/(pinitol diacetonide) SR-A
D-(+)-pinitol (3.0 g, 15.5 mmol, 1 eq) was taken in acetone
(30 mL) and p-toluene sulfonic acid monohydrate (0.94 g,
5 mmol, 0.3 eq) and 2,2-dimethoxy propane (5.7 mL,
46.5 mmol, 3 eq) were added with stirring. After completion
of the reaction (2 h), triethylamine (1 mL) was added and the
solvents were removed in vacuo. The residue was subjected to
column chromatography using hexane:ethyl acetate (8:2) as
mobile phase to give SR-A as white crystalline solid (4.2 g,
15.3 mmol). Yield: 96%; mp. 132 C; 1H NMR (400 MHz,
CDCl3) d: 4.23 (4H, m), 3.59 (4H, s), 3.22 (1H, dd, J= 6.0,
5.2), 1.51 (6H, s), 1.37 (6H, s); 13C NMR (100 MHz, CDCl3)
d: 110.2, 110.0, 81.5, 79, 78, 77.1, 76.8, 71.6, 59.3, 29.9, 29.4,
25.4, 25.3; HR-ESIMS m/z calcd for C13H22O6 [M+ H]
+
275.1424, found 275.1488.
4.1.2. Preparation of 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-
4-propargyl-D-chiro-inositol SR-B
To a solution of diacetonide (SR-A) (2.0 g, 7.3 mmol, 1.0 eq)
in acetonitrile (10 mL), NaH (192 mg, 8.7 mmol, 1.2 eq) was
added portionwise and stirred for 15 min at 0 C. Solution of
propargyl bromide (0.82 mL, 10.9 mmol, 1.5 eq) in acetone
(3.0 mL) was then added and the suspension was stirred for
6 h. Progress of reaction was monitored using TLC in
hexane:ethyl acetate (9:1) at regular intervals. After the
completion of reaction, the product was extracted with ethyl
acetate (30 mL  3) which on subsequent purification over
silica gel column resulted in the isolation of pure product
SR-B in 90% yield. Cream colored solid; Yield: 93%; mp.
117 C; 1H NMR (400 MHz, CDCl3) d: 4.46 (m, 2H), 4.24
(s, 2H), 4.19 (m, 1H), 3.59 (s, 3H), 3.54 (m, 1H), 3.30d facile synthesis and bioevaluation of novel triazolyl analogs of D-(+)-pinitol.
6 Shakeel-u-Rehman et al.(m, 1H), 2.45 (s, 1H), 1.52 (s, 6H), 1.35 (s, 6H); 13C NMR
(100 MHz, CDCl3) d: 109.75, 109.65, 81.55, 79.90, 78.87,
78.72, 78.60, 76.42, 76.35, 74.46, 59.85, 58.85, 27.81, 27.74,
25.33, 25.28; HR-ESIMS m/z calcd for C16H24O6 [M+H]
+
313.1583, found 313.1632.
4.1.3. General procedure for synthesis of azides
To a solution of particular aromatic amine in 1,4-dioxane (at
the concentration of 50 mg/mL) at 15.0 C, 5 equivalents
of 2 M Sulphuric acid was added in small instalments while
stirring. After 5 min 2 equivalents of 3 M sodium nitrite was
added drop wise and after 30 min 3 equivalents of 3 M sodium
azide was added drop wise carefully. Reaction was brought to
room temperature and extracted with diethyl ether for at least
three times. Organic layers were washed with saturated sodium
bicarbonate solution two times, dried over anhydrous sodium
sulphate and concentrated to a minimum volume under
reduced pressure on Rotary evaporator without making use
of heating from water bath (Dedola et al., 2010).
4.1.4. General procedure for synthesis of triazolyl derivatives
1–25 and 1a–25a
To a solution of SR-B (50 mg, 0.16 mmol, 1 eq) in t-BuOH:
H2O (2:1, 5 mL), sodium ascorbate (4.0 mg, 0.024 mmol) and
CuSO4_s5H2O (4 mg, 0.015 mmol) were added at room temper-
ature. To this mixture, freshly prepared organic azides
(0.24 mmol) were added and the reaction mixture was soni-
cated till its completion. The crude mixture was extracted with
ethyl acetate (3  20 mL) and the combined organic layer was
dried over sodium sulphate and purified through column chro-
matography to give pure 1–25 in 88–96% yield. 1–25 (25 mg
each) were further treated with trifluoroacetic acid:H2O (1:1;
5 mL) for the deprotection of 1,2 and 5,6 hydroxyls and the
reaction mixture was allowed to stir at room temperature for
3 h to afford corresponding analogs (1a–25a) in 44–59% yield.
4.1.4.1. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(4-met-
hoxyphenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-inositol 1.
Colorless liquid; Yield: 96%; 1H NMR (400 MHz, CDCl3) d:
8.02 (s, 1H), 7.63 (d, J= 8.8 Hz, 2H), 7.02 (d, J= 8.8 Hz,
2H), 5.05 (m, 2H), 4.59 (m, 4H), 3.87 (s, 3H), 3.61 (s, 3H),
3.55 (m, 1H), 3.33 (m, 1H), 1.52 (s, 3H), 1.46 (s, 3H), 1.35
(s, 6H); 13C NMR (100 MHz, CDCl3) d: 159.73, 146.16,
130.58, 122.11, 122.11, 121.03, 114.74, 114.74, 109.74, 109.74,
81.59, 79.68, 78.89, 78.89, 76.55, 76.48, 65.42, 59.98, 55.62,
27.80, 27.74, 25.31, 25.28; HR-ESIMS m/z calcd for
C23H31N3O7 [M+H]
+ 462.2173, found 462.2202.
4.1.4.2. 3-O-Methyl-4-[1-{(4-methoxyphenyl)-1H-1,2,3-tria-
zol-4yl}methoxy]-D-chiro-inositol 1a. Colorless liquid; Yield:
48%; 1H NMR (400 MHz, CDCl3) d: 8.09 (s, 1H), 7.65 (d,
J= 8.8 Hz, 2H), 7.08 (d, J= 8.8 Hz, 2H), 5.07 (m, 2H),
4.62 (m, 4H), 3.89 (s, 3H), 3.61 (s, 3H), 3.56 (m, 1H), 3.36
(m, 1H); HR-ESIMS m/z calcd for C17H23N3O7 [M+H]
+
382.1548, found 382.1598.4.1.4.3. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(4-bro-
mophenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-inositol 2.
Yellowish liquid; Yield: 91%; 1H NMR (400 MHz, CDCl3)
d: 8.09 (s, 1H), 7.66 (d, J= 9.1 Hz, 2H), 7.63 (d,Please cite this article in press as: Shakeel-u-Rehman, et al., Click chemistry inspire
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3.55 (m, 1H), 3.33 (m, 1H), 1.52 (s, 3H), 1.46 (s, 3H), 1.35
(s, 6H); 13C NMR (100 MHz, CDCl3) d: 146.15, 135.12,
131.91, 131.91, 121.28, 120.80, 120.80, 119.59, 108.72, 108.72,
80.70, 78.81, 77.96, 77.89, 75.57, 75.49, 64.40, 58.94, 26.79,
26.74, 24.30, 24.28; HR-ESIMS m/z calcd for C22H28BrN3O6
[M+ H]+ 510.1169, found 510.1208.
4.1.4.4. 3-O-Methyl-4-[1-{(4-bromophenyl)-1H-1,2,3-triazol-
4yl}methoxy]-D-chiro-inositol 2a. Yellowish liquid; Yield:
52%; 1H NMR (400 MHz, CDCl3) d: 8.12 (s, 1H), 7.69 (d,
J= 9.1 Hz, 2H), 7.65 (d, J= 9.1 Hz, 2H), 5.09 (m, 2H),
4.27 (m, 4H), 3.63 (s, 3H), 3.57 (m, 1H), 3.34 (m, 1H);
HR-ESIMS m/z calcd for C16H20BrN3O6 [M+H]
+
430.0543, found 430.0603.
4.1.4.5. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(2,5-
dimethylphenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-inositol
3. Colorless liquid; Yield: 94%; 1H NMR (400 MHz, CDCl3)
d: 7.82 (s, 1H), 7.21 (d, J= 8 Hz, 1H), 7.07 (m, 1H), 6.97
(m, 1H), 5.07 (m, 2H), 4.24 (m, 4H), 3.61 (s, 3H), 3.55
(m, 1H), 3.33 (m, 1H), 2.37 (s, 3H), 2.19 (s, 3H), 1.52 (s,
3H), 1.49 (s, 3H), 1.35 (s, 6H); 13C NMR (100 MHz, CDCl3)
d: 145.87, 138.69, 137.68, 134.51, 134.51, 133.35, 133.05,
123.97, 109.77, 109.74, 81.67, 79.89, 78.96, 78.96, 76.61,
76.56, 65.43, 59.96, 27.81, 27.81, 25.33, 25.30, 17.77, 17.62;
HR-ESIMS m/z calcd for C24H33N3O6 [M+ H]
+ 460.2388,
found 460.2444.
4.1.4.6. 3-O-Methyl-4-[1-{(2,5-dimethylphenyl)-1H-1,2,3-tria-
zol-4yl}methoxy]-D-chiro-inositol 3a. Colorless liquid; Yield:
50%; 1H NMR (400 MHz, CDCl3) d: 7.85 (s, 1H), 7.20 (d,
J= 8.2 Hz, 1H), 7.05 (m, 1H), 6.95 (m, 1H), 5.08 (m, 2H),
4.25 (m, 4H), 3.63 (s, 3H), 3.57 (m, 1H), 3.35 (m, 1H), 2.33
(s, 3H), 2.20 (s, 3H); HR-ESIMS m/z calcd for C18H25N3O6
[M+ H]+ 380.1754, found 380.2071.
4.1.4.7. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(2-bro-
mophenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-inositol 4.
Yellowish liquid; Yield: 88%; 1H NMR (400 MHz, CDCl3)
d: 8.06 (s, 1H), 7.75 (m, 1H), 7.55 (m, 1H), 7.49 (m, 1H),
7.38 (m, 1H), 5.08 (m, 2H), 4.25 (m, 4H), 3.61 (s, 3H), 3.58
(m, 1H), 3.33 (m, 1H), 1.52 (s, 3H), 1.49 (s, 3H), 1.35 (s,
6H); 13C NMR (100 MHz, CDCl3) d: 145.29, 136.70, 133.94,
131.07, 128.48, 128.20, 124.73, 118.48, 109.78, 109.72, 81.59,
79.95, 79.02, 78.91, 76.60, 76.55, 65.35, 60.03, 27.81, 27.81,
25.34, 25.30; HR-ESIMS m/z calcd for C22H28BrN3O6
[M+ H]+ 510.1171, found 510.2012.
4.1.4.8. 3-O-Methyl-4-[1-{(2-bromophenyl)-1H-1,2,3-triazol-
4yl}methoxy]-D-chiro-inositol 4a. Yellowish liquid; Yield:
48%; 1H NMR (400 MHz, CDCl3) d: 8.09 (s, 1H), 7.77 (m,
1H), 7.58 (m, 1H), 7.50 (m, 1H), 7.41 (m, 1H), 5.09 (m, 2H),
4.26 (m, 4H), 3.63 (s, 3H), 3.59 (m, 1H), 3.35 (m, 1H); HR-
ESIMS m/z calcd for C16H20BrN3O6 [M+ H]
+ 430.0544,
found 430.1007.
4.1.4.9. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(phe-
nyl)-1H-1,2,3-triazol-4yl} methoxy]-D-chiro-inositol 5. Color-
less liquid; Yield: 94%; 1H NMR (400 MHz, CDCl3) d: 8.11
(s, 1H), 7.74 (m, 2H), 7.53 (m, 2H), 7.44 (m, 1H), 5.06 (m,
2H), 4.22 (m, 4H), 3.62 (s, 3H), 3.58 (m, 1H), 3.35 (m, 1H),d facile synthesis and bioevaluation of novel triazolyl analogs of D-(+)-pinitol.
Facile synthesis & bioevaluation of pinitol triazoles 71.52 (s, 3H), 1.47 (s, 3H), 1.35 (s, 6H); 13C NMR (100 MHz,
CDCl3) d: 146.50, 137.19, 129.75, 129.75, 128.68, 120.83,
120.48, 120.48, 109.75, 109.73, 81.69, 79.79, 78.95, 78.95,
76.61, 76.54, 65.46, 59.98, 27.82, 27.75, 25.33, 25.30; HR-
ESIMS m/z calcd for C22H29N3O6 [M+H]
+ 432.2064, found
432.2130.
4.1.4.10. 3-O-Methyl-4-[1-{(phenyl)-1H-1,2,3-triazol-4yl}
methoxy]-D-chiro-inositol 5a. Colorless liquid; Yield: 44%;
1H NMR (400 MHz, CDCl3) d: 8.13 (s, 1H), 7.75 (m, 2H),
7.55 (m, 2H), 7.47 (m, 1H), 5.09 (m, 2H), 4.20 (m, 4H), 3.63
(s, 3H), 3.55 (m, 1H), 3.36 (m, 1H); HR-ESIMS m/z calcd
for C16H21N3O6 [M+H]
+ 352.1438, found 352.1522.
4.1.4.11. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(4-
cyanophenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-inositol
6. Colorless liquid; Yield: 95%; 1H NMR (400 MHz, CDCl3)
d: 8.20 (s, 1H), 7.92 (d, J= 8.8 Hz, 2H), 7.86 (d,
J= 8.8 Hz, 2H), 5.08 (m, 2H), 4.23 (m, 4H), 3.62 (s, 3H),
3.53 (m, 1H), 3.33 (m, 1H), 1.52 (s, 3H), 1.46 (s, 3H), 1.35
(s, 6H). 13C NMR (100 MHz, CDCl3) d: 147.49, 139.93,
133.96, 133.96, 120.44, 120.44, 120.40, 117.71, 112.35, 109.76,
109.74, 81.72, 79.91, 78.98, 78.88, 76.56, 76.47, 65.36, 59.95,
27.82, 27.76, 25.32, 25.32; HR-ESIMS m/z calcd for
C23H28N4O6 [M+ H]
+ 457.2017, found 457.2088.
4.1.4.12. 3-O-Methyl-4-[1-{(4-cyanophenyl)-1H-1,2,3-triazol-
4yl}methoxy]-D-chiro-inositol 6a. Colorless liquid; Yield:
47%; 1H NMR (400 MHz, CDCl3) d: 8.19 (s, 1H), 7.91 (d,
J= 8.8 Hz, 2H), 7.83 (d, J= 8.8 Hz, 2H), 5.09 (m, 2H),
4.25 (m, 4H), 3.63 (s, 3H), 3.55 (m, 1H), 3.35 (m, 1H); HR-
ESIMS m/z calcd for C17H20N4O6 [M+H]
+ 377.1392, found
377.1421.
4.1.4.13. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(3-
cyanomethylphenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-
inositol 7. Colorless liquid; Yield: 94%; 1H NMR (400 MHz,
CDCl3) d: 8.13 (s, 1H), 7.78 (s, 1H), 7.64 (d, J= 8.0 Hz,
1H), 7.50 (t, J= 8 Hz, 1H), 7.43 (t, J= 8.0 Hz, 1H), 5.06
(m, 2H), 4.81 (s, 2H), 4.29 (m, 2H), 4.23 (m, 3H), 3.62 (s,
3H), 3.55 (m, 1H), 3.33 (m, 1H), 1.52 (s, 3H), 1.47 (s, 3H),
1.35 (s, 6H); 13C NMR (100 MHz, CDCl3) d: 146.46, 143.11,
137.31, 129.87, 126.81, 120.88, 119.40, 118.67, 114.1, 109.77,
109.75, 81.65, 79.79, 78.92, 78.91, 76.58, 76.51, 65.41, 64.41,
59.97, 27.81, 27.75, 25.32, 25.29; HR-ESIMS m/z calcd for
C24H30N4O6 [M+ H]
+ 471.2173, found 471.2232.
4.1.4.14. 3-O-Methyl-4-[1-{(3-cyanomethylphenyl)-1H-1,2,3-
triazol-4yl}methoxy]-D-chiro-inositol 7a. Colorless liquid;
Yield: 49%; 1H NMR (400 MHz, CDCl3) d: 8.11 (s, 1H),
7.77 (s, 1H), 7.65 (d, J= 8.2 Hz, 1H), 7.51 (t, J= 8.2 Hz,
1H), 7.44 (t, J= 8.2 Hz, 1H), 5.09 (m, 2H), 4.81 (s, 2H),
4.29 (m, 2H), 4.25 (m, 3H), 3.63 (s, 3H), 3.55 (m, 1H), 3.34
(m, 1H); HR-ESIMS m/z calcd for C18H22N4O6 [M+ H]
+
391.1548, found 391.1627.
4.1.4.15. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(2-
nitrophenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-inositol 8.
Yellow liquid; Yield: 88%; 1H NMR (400 MHz, CDCl3) d:
8.08 (d, J= 8.0 Hz, 1H), 7.97 (s, 1H), 7.80 (t, J= 8.0 Hz,
1H), 7.69 (m, 2H), 5.08 (m, 2H), 4.30 (m, 1H), 4.23 (m, 3H),
3.61 (s, 3H), 3.55 (m, 1H), 3.33 (m, 1H), 1.52 (s, 3H), 1.49Please cite this article in press as: Shakeel-u-Rehman, et al., Click chemistry inspire
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144.41, 133.80, 130.63, 130.37, 127.62, 125.45, 124.21, 109.64,
109.64, 81.49, 79.85, 78.96, 78.90, 76.60, 76.53, 65.25, 59.74,
27.81, 27.76, 25.31, 25.29; HR-ESIMS m/z calcd for
C22H28N4O8 [M+H]
+ 477.1916, found 477.2004.
4.1.4.16. 3-O-Methyl-4-[1-{(2-nitrophenyl)-1H-1,2,3-triazol-
4yl}methoxy]-D-chiro-inositol 8a. Yellow liquid; Yield: 48%;
1H NMR (400 MHz, CDCl3) d: 8.11 (d, J= 8.0 Hz, 1H),
7.99 (s, 1H), 7.82 (t, J= 8.0 Hz, 1H), 7.71 (m, 2H), 5.09 (m,
2H), 4.33 (m, 1H), 4.25 (m, 3H), 3.62 (s, 3H), 3.57 (m, 1H),
3.34 (m, 1H); HR-ESIMS m/z calcd for C16H20N4O8 [M
+H]+ 397.1297, found 397.1321.
4.1.4.17. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(2-
methoxyphenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-inositol
9. Yellow liquid; Yield: 88%; 1H NMR (400 MHz, CDCl3) d:
8.2 (s, 1H), 7.77 (d, J= 8 Hz, 1H), 7.42 (m, 1H), 7.10 (m, 2H),
5.05 (m, 2H), 4.31 (m, 1H), 4.22 (m, 3H), 3.89 (s, 3H), 3.62
(s, 3H), 3.55 (m, 1H), 3.33 (m, 1H), 1.52 (s, 3H), 1.47
(s, 3H), 1.35 (s, 6H); 13C NMR (100 MHz, CDCl3) d: 151.11,
130.03, 126.31, 125.66, 125.50, 121.33, 121.21, 112.19, 109.74,
109.70, 81.48, 79.78, 79.02, 78.82, 76.54, 76.48, 65.30, 60.05,
55.92, 27.80, 27.75, 25.34, 25.28; HR-ESIMS m/z calcd for
C23H31N3O7 [M+H]
+ 462.2170, found 462.2207.
4.1.4.18. 3-O-Methyl-4-[1-{(2-methoxyphenyl)-1H-1,2,3-tria-
zol-4yl}methoxy]-D-chiro-inositol 9. Yellow liquid; Yield:
47%; 1H NMR (400 MHz, CDCl3) d: 8.19 (s, 1H), 7.78 (d,
J= 8.2 Hz, 1H), 7.43 (m, 1H), 7.11 (m, 2H), 5.07 (m, 2H),
4.33 (m, 1H), 4.21 (m, 3H), 3.87 (s, 3H), 3.60 (s, 3H), 3.59
(m, 1H), 3.38 (m, 1H); HR-ESIMS m/z calcd for
C17H23N3O7 [M+H]
+ 382.1543, found 382.1603.
4.1.4.19. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(2-
chlorophenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-inositol
10. Colorless liquid; Yield: 89%; 1H NMR (400 MHz, CDCl3)
d: 8.1 (s, 1H), 7.76 (d, J= 8 Hz, 1H), 7.40 (m, 1H), 7.12 (m,
2H), 5.05 (m, 2H), 4.31 (m, 1H), 4.20 (m, 3H), 3.62 (s, 3H),
3.55 (m, 1H), 3.33 (m, 1H), 1.52 (s, 3H), 1.47 (s, 3H), 1.35
(s, 6H); 13C NMR (100 MHz, CDCl3) d: 145.47, 134.97,
130.78, 130.66, 128.45, 127.93, 127.73, 124.68, 109.79, 109.74,
81.52, 79.88, 78.96, 78.87, 76.56, 76.51, 65.31, 60.02, 27.80,
27.77, 25.31, 25.28; HR-ESIMS m/z calcd for C22H28ClN3O6
[M+H]+ 466.1675, found 466.1808.
4.1.4.20. 3-O-Methyl-4-[1-{(2-chlorophenyl)-1H-1,2,3-triazol-
4yl}methoxy]-D-chiro-inositol 10a. Colorless liquid; Yield:
48%; 1H NMR (400 MHz, CDCl3) d: 8.13 (s, 1H), 7.79 (d,
J= 8 Hz, 1H), 7.42 (m, 1H), 7.13 (m, 2H), 5.07 (m, 2H),
4.35 (m, 1H), 4.23 (m, 3H), 3.64 (s, 3H), 3.57 (m, 1H), 3.38
(m, 1H); HR-ESIMS m/z calcd for C16H20ClN3O6 [M
+H]+ 386.1050, found 386.1108.
4.1.4.21. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(2-
hydroxymethylphenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-
inositol 11. Colorless liquid; Yield: 92%; 1H NMR (400 MHz,
CDCl3) d: 8.05 (s, 1H), 7.64 (d, J= 8.0 Hz, 1H), 7.50 (m, 2H),
7.40 (d, J= 8.0 Hz, 1H), 5.08 (m, 2H), 4.49 (s, 2H), 4.31 (m,
1H), 4.24 (m, 3H), 3.62 (s, 3H), 3.57 (m, 1H), 3.33 (m, 1H),
1.52 (s, 3H), 1.49 (s, 3H), 1.36 (s, 6H); 13C NMR (100 MHz,
CDCl3) d: 146.10, 136.12, 135.59, 131.73, 129.96, 129.17,d facile synthesis and bioevaluation of novel triazolyl analogs of D-(+)-pinitol.
8 Shakeel-u-Rehman et al.124.29, 124.06, 109.82, 109.76, 81.6, 79.85, 78.93, 78.93, 76.55,
76.49, 65.32, 61.89, 59.99, 27.81, 27.79, 25.32, 25.30;
HR-ESIMS m/z calcd for C23H31N3O7 [M+ H]
+ 462.2170,
found 462.2208.
4.1.4.22. 3-O-Methyl-4-[1-{(2-hydroxymethylphenyl)-1H-
1,2,3-triazol-4yl}methoxy]-D-chiro-inositol 11a. Colorless
liquid; Yield: 49%; 1H NMR (400 MHz, CDCl3) d: 8.09 (s,
1H), 7.67 (d, J= 8.2 Hz, 1H), 7.53 (m, 2H), 7.42 (d,
J= 8.2 Hz, 1H), 5.09 (m, 2H), 4.50 (s, 2H), 4.33 (m, 1H),
4.27 (m, 3H), 3.63 (s, 3H), 3.61 (m, 1H), 3.35 (m, 1H);
HR-ESIMS m/z calcd for C17H23N3O7 [M+ H]
+ 382.1544,
found 382.1599.
4.1.4.23. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(4-
acetamidophenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-inos-
itol 12. Cream colored solid; Yield: 92%; mp: 145 C; 1H
NMR (400 MHz, CDCl3) d: 8.06 (s, 1H), 7.68 (d,
J= 8.8 Hz, 2H), 7.64 (d, J= 8.8, Hz, 2H), 5.05 (m, 2H),
4.29 (m, 2H), 4.22 (s, 2H), 3.61 (s, 3H), 3.55 (m, 1H), 3.34
(m, 1H), 2.22 (s, 3H), 1.52, (s, 3H), 1.46 (s, 3H), 1.35(s, 6H);
13C NMR (100 MHz, CDCl3) d 168.71, 146.36, 138.56,
132.97, 121.15, 121.15, 120.91, 120.63, 120.63, 109.77, 109.77,
81.67, 79.79, 78.97, 78.92, 76.61, 76.55, 65.33, 59.89, 27.81,
27.75, 25.31, 25.31, 24.59; HR-ESIMS m/z calcd for
C24H32N4O7 [M+H]
+ 489.2280, found 489.2322.
4.1.4.24. 3-O-Methyl-4-[1-{(4-acetamidophenyl)-1H-1,2,3-tri-
azol-4yl}methoxy]-D-chiro-inositol 12a. Cream colored solid;
Yield: 46%; mp: 133 C; 1H NMR (400 MHz, CDCl3) d:
8.08 (s, 1H), 7.71 (d, J= 8.7 Hz, 2H), 7.65 (d, J= 8.7 Hz,
2H), 5.09 (m, 2H), 4.34 (m, 2H), 4.25 (s, 2H), 3.63 (s, 3H),
3.57 (m, 1H), 3.35 (m, 1H), 2.23 (s, 3H); HR-ESIMS m/z calcd
for C18H24N4O7 [M+ H]
+ 409.1653, found 409.1694.
4.1.4.25. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(4-
cyanomethylphenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-
inositol 13. Cream colored liquid; Yield: 93%; 1H NMR
(400 MHz, CDCl3) d: 8.25 (d, J= 8.6 Hz, 2H), 8.21 (s, 1H),
7.87 (d, J= 8.6 Hz, 2H), 5.06 (m, 2H), 4.25 (m, 6H), 3.63 (s,
3H), 3.56 (m, 1H), 3.35 (m, 1H), 1.53 (s, 3H), 1.48 (s, 3H),
1.36 (s, 6H); 13C NMR (100 MHz, CDCl3) d: 147.07, 140.54,
131.97, 131.97, 129.48, 120.64, 119.83, 119.83, 113.9, 109.81,
109.78, 81.72, 79.82, 78.96, 78.90, 76.59, 76.50, 65.33, 63.10,
59.94, 27.82, 27.76, 25.32, 25.32. HR-ESIMS m/z calcd for
C24H30N4O6 [M+H]
+ 471.2173, found 471.2213.
4.1.4.26. 3-O-Methyl-4-[1-{(4-cyanomethylphenyl)-1H-1,2,3-
triazol-4yl}methoxy]-D-chiro-inositol 13a. Cream colored
liquid; Yield: 50%; 1H NMR (400 MHz, CDCl3) d: 8.24 (d,
J= 8.6 Hz, 2H), 8.22 (s, 1H), 7.89 (d, J= 8.6 Hz, 2H), 5.08
(m, 2H), 4.29 (m, 6H), 3.65 (s, 3H), 3.57 (m, 1H), 3.35 (m,
1H); HR-ESIMS m/z calcd for C18H22N4O6 [M+H]
+
391.1547, found 391.1593.
4.1.4.27. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(4-
benzoylphenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-inositol
14. Cream colored solid; Yield: 94%; mp: 157 C; 1H NMR
(400 MHz, CDCl3) d: 8.22 (s, 1H), 7.99 (d, J= 8.6 Hz, 2H),
7.90 (d, J= 8.4 Hz, 2H), 7.82 (d, J= 8.6 Hz, 2H), 7.63 (m,
1H), 7.53 (m, 2H), 5.10 (m, 2H), 4.27 (m, 4H), 3.63 (s, 3H),
3.56 (m, 1H), 3.35 (m, 1H), 1.53 (s, 3H), 1.47 (s, 3H), 1.36Please cite this article in press as: Shakeel-u-Rehman, et al., Click chemistry inspire
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139.74, 137.44, 137.10, 132.86, 131.78, 131.78, 130.00, 130.00,
128.52, 128.52, 119.78, 119.78, 109.75, 109.75, 81.72, 79.87,
78.98, 78.91, 76.59, 76.51, 65.43, 59.97, 27.82, 27.77, 25.33,
25.31; HR-ESIMS m/z calcd for C29H33N3O7 [M+H]
+
536.2327, found 536.2397.
4.1.4.28. 3-O-Methyl-4-[1-{(4-benzoylphenyl)-1H-1,2,3-tria-
zol-4yl}methoxy]-D-chiro-inositol 14a. Cream colored solid;
Yield: 52%; mp: 144 C; 1H NMR (400 MHz, CDCl3) d:
8.23 (s, 1H), 8.01 (d, J= 8.6 Hz, 2H), 7.90 (d, J= 8.4 Hz,
2H), 7.83 (d, J= 8.6 Hz, 2H), 7.65 (m, 1H), 7.54 (m, 2H),
5.11 (m, 2H), 4.31 (m, 4H), 3.65 (s, 3H), 3.57 (m, 1H), 3.37
(m, 1H); HR-ESIMS m/z calcd for C23H25N3O7 [M+H]
+
456.1705, found 456.1755.
4.1.4.29. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(4-
benzamidophenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-inos-
itol 15. Cream colored solid; Yield: 90%; mp: 188 C; 1H
NMR (400 MHz, CDCl3) d: 8.08 (s, 1H), 7.90 (m, 2H), 7.84
(d, J= 8.3 Hz, 2H), 7.73 (d, J= 8.3 Hz, 2H), 7.58 (m, 1H),
7.52 (m, 2H), 5.06 (m, 2H), 4.30 (m, 2H), 4.22 (s, 2H), 3.62
(s, 3H), 3.54 (m, 1H), 3.33 (m, 1H), 1.52 (s, 3H), 1.47 (s,
3H), 1.35 (s, 6H); 13C NMR (101 MHz, CDCl3) d: 165.87,
146.16, 139.28, 138.40, 134.49, 133.35, 132.22, 128.92, 128.92,
127.11, 127.11, 121.21, 121.21, 121.07, 121.07, 109.76, 109.74,
81.70, 79.81, 78.97, 78.93, 76.62, 76.55, 65.43, 59.94, 27.81,
27.76, 25.32, 25.30; HR-ESIMS m/z calcd for C29H34N4O7
[M+ H]+ 551.2435, found 551.2509.
4.1.4.30. 3-O-Methyl-4-[1-{(4-benzamidophenyl)-1H-1,2,3-tri-
azol-4yl}methoxy]-D-chiro-inositol 15a. Cream colored solid;
Yield: 59%; mp: 157 C; 1H NMR (400 MHz, CDCl3) d:
8.11 (s, 1H), 7.92 (m, 2H), 7.85 (d, J= 8.3 Hz, 2H), 7.75 (d,
J= 8.3 Hz, 2H), 7.59 (m, 1H), 7.54 (m, 2H), 5.07 (m, 2H),
4.31 (m, 2H), 4.24 (s, 2H), 3.63 (s, 3H), 3.57 (m, 1H), 3.33
(m, 1H); HR-ESIMS m/z calcd for C23H26N4O7 [M+H]
+
471.1809, found 471.1863.
4.1.4.31. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(3,4,5-
trimethoxyphenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-inositol
16. Colorless liquid; Yield: 93%; 1H NMR (400 MHz, CDCl3)
d: 8.05 (s, 1H), 6.95 (s, 1H), 5.05 (m, 2H), 4.24 (m, 4H), 3.93
(s, 6H), 3.89 (s, 3H), 3.62 (s, 3H), 3.56 (m, 1H), 3.33
(m, 1H), 1.52 (s, 3H), 1.47 (s, 3H), 1.35 (s, 6H); 13C NMR
(100 MHz, CDCl3) d: 153.88, 153.88, 146.42, 138.12, 133.00,
121.09, 109.72, 109.72, 98.42, 98.42, 81.62, 79.80, 78.91,
78.85, 76.51, 76.41, 65.42, 61.07, 59.93, 56.42, 56.42, 27.81,
27.78, 25.35, 25.31; HR-ESIMS m/z calcd for C25H35N3O9
[M+ H]+ 522.2381 found 522.2505.
4.1.4.32. 3-O-Methyl-4-[1-{(3,4,5-trimethoxyphenyl)-1H-1,2,3-
triazol-4yl}methoxy]-D-chiro-inositol 16a. Colorless liquid;
Yield: 53%; 1H NMR (400 MHz, CDCl3) d: 8.09 (s, 1H),
7.01 (s, 1H), 5.09 (m, 2H), 4.29 (m, 4H), 3.91 (s, 6H), 3.86
(s, 3H), 3.63 (s, 3H), 3.58 (m, 1H), 3.35 (m, 1H); HR-ESIMS
m/z calcd for C19H27N3O9 [M+H]
+ 442.1755, found
442.2027.
4.1.4.33. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(5-
iodo-2-methylphenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-
inositol 17. Colorless liquid; Yield: 88%; 1H NMR (400 MHz,d facile synthesis and bioevaluation of novel triazolyl analogs of D-(+)-pinitol.
Facile synthesis & bioevaluation of pinitol triazoles 9CDCl3) d: 7.84 (s, 1H), 7.72 (m, 2H), 7.12 (d, J= 8.0 Hz, 1H),
5.06 (m, 2H), 4.26 (m, 4H), 3.61 (s, 3H), 3.56 (m, 1H), 3.33 (m,
1H), 2.20 (s, 3H), 1.52 (s, 3H), 1.49 (s, 3H), 1.35 (s, 6H); 13C
NMR (100 MHz, CDCl3) d: 145.76, 138.66, 137.58, 134.51,
134.51, 133.35, 133.05, 123.97, 109.77, 109.74, 81.67, 79.89,
78.96, 78.96, 76.61, 76.56, 65.43, 59.96, 27.81, 27.81, 25.33,
25.30, 17.77; HR-ESIMS m/z calcd for C23H30IN3O6 [M
+ H]+ 572.1187, found 572.1213.
4.1.4.34. 3-O-Methyl-4-[1-{(5-iodo-2-methylphenyl)-1H-1,2,3-
triazol-4yl}methoxy]-D-chiro-inositol 17a. Colorless liquid;
Yield: 88%; 1H NMR (400 MHz, CDCl3) d: 7.91 (s, 1H),
7.77 (m, 2H), 7.18 (d, J= 8.0 Hz, 1H), 5.09 (m, 2H), 4.27
(m, 4H), 3.63 (s, 3H), 3.57 (m, 1H), 3.38 (m, 1H), 2.23 (s,
3H); HR-ESIMS m/z calcd for C17H22IN3O6 [M+ H]
+
492.0561, found 492.0607.
4.1.4.35. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(1-
octyl)-1H-1,2,3-triazol-4yl} methoxy]-D-chiro-inositol 18.
Colorless liquid; Yield: 89%; 1H NMR (400 MHz, CDCl3) d:
7.62 (s, 1H), 4.97 (m, 2H), 4.22 (m, 2H), 4.24 (m, 4H), 3.59
(s, 3H), 3.52 (m, 1H), 3.30 (m, 1H), 1.90 (m, 2H), 1.51 (s,
3H), 1.47 (s, 3H), 1.34 (s, 6H), 1.25 (m, 13H); 13C NMR
(101 MHz, CDCl3) d: 145.75, 136.62, 109.70, 109.70, 81.60,
79.75, 78.99, 78.90, 76.60, 76.54, 65.52, 59.94, 50.34, 31.84,
30.31, 29.24, 29.01, 27.80, 27.77, 26.52, 25.32, 25.28, 22.65,
14.09; HR-ESIMS m/z calcd for C24H41N3O6 [M+ H]
+
468.3003, found 468.3037.
4.1.4.36. 3-O-Methyl-4-[1-{(1-octyl)-1H-1,2,3-triazol-4yl}
methoxy]-D-chiro-inositol 18a. Colorless liquid; Yield: 49%;
1H NMR (400 MHz, CDCl3) d: 7.69 (s, 1H), 5.01 (m, 2H),
4.25 (m, 2H), 4.29 (m, 4H), 3.61 (s, 3H), 3.50 (m, 1H), 3.35
(m, 1H), 1.91 (m, 2H), 1.27 (m, 13H); HR-ESIMS m/z calcd
for C18H33N3O6 [M+H]
+ 388.2377, found 388.2412.
4.1.4.37. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(3-
methoxyphenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-inositol
19. Colorless liquid; Yield: 92%; 1H NMR (400 MHz, CDCl3)
d: 8.10 (s, 1H), 7.38 (m, 2H), 7.25 (m, 1H), 6.97 (m, 1H), 5.06
(m, 2H), 4.23 (m, 4H), 3.88 (s, 3H), 3.62 (s, 3H), 3.55 (m, 1H),
3.35 (m, 1H), 1.52 (s, 3H), 1.47 (s, 3H), 1.35 (s, 6H); 13C NMR
(100 MHz, CDCl3) d: 145.96, 137.91, 130.49, 120.91, 119.76,
114.49, 112.29, 109.74, 109.72, 106.21, 81.65, 79.92, 78.91,
78.91, 76.57, 76.50, 65.41, 59.78, 55.62, 27.80, 27.74, 25.31,
25.28. HR-ESIMS m/z calcd for C23H31N3O7 [M+ H]
+
462.2170, found 462.2212.
4.1.4.38. 3-O-Methyl-4-[1-{(3-methoxyphenyl)-1H-1,2,3-tria-
zol-4yl}methoxy]-D-chiro-inositol 19a. Colorless liquid; Yield:
52%; 1H NMR (400 MHz, CDCl3) d: 8.11 (s, 1H), 7.41 (m,
2H), 7.27 (m, 1H), 6.99 (m, 1H), 5.08 (m, 2H), 4.31 (m, 4H),
3.91 (s, 3H), 3.63 (s, 3H), 3.57 (m, 1H), 3.34 (m, 1H);
HR-ESIMS m/z calcd for C17H23N3O7 [M+H]
+ 382.1544,
found 382.1601.
4.1.4.39. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(2,4,
5-trichlorophenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-inos-
itol 20. Dark brown liquid; Yield: 90%; 1H NMR (400 MHz,
CDCl3) d: 8.13 (s, 1H), 7.80 (s, 1H), 7.71 (s, 1H), 5.08 (m,
2H), 4.23 (m, 4H), 3.60 (s, 3H), 3.55 (m, 1H), 3.32 (m, 1H),
1.52 (s, 3H), 1.48 (s, 3H), 1.35 (s, 6H); 13C NMR (100 MHz,Please cite this article in press as: Shakeel-u-Rehman, et al., Click chemistry inspire
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126.80, 124.35, 109.80, 109.76, 81.54, 79.94, 78.93, 78.90,
76.54, 76.48, 65.23, 60.00, 27.80, 27.78, 25.31, 25.29;
HR-ESIMS m/z calcd for C22H26Cl3N3O6 [M+ H]
+
534.0895, found 534.1023.
4.1.4.40. 3-O-Methyl-4-[1-{(2,4,5-trichlorophenyl)-1H-1,2,3-
triazol-4yl}methoxy]-D-chiro-inositol 20a. Brown liquid; Yield:
51%; 1H NMR (400 MHz, CDCl3) d: 8.11 (s, 1H), 7.82 (s, 1H),
7.73 (s, 1H), 5.08 (m, 2H), 4.25 (m, 4H), 3.65 (s, 3H), 3.57 (m,
1H), 3.37 (m, 1H); HR-ESIMS m/z calcd for C16H18Cl3N3O6
[M+H]+ 454.0269, found 454.0403.
4.1.4.41. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(ben-
zyl)-1H-1,2,3-triazol-4yl} methoxy]-D-chiro-inositol 21. Color-
less liquid; Yield: 89%; 1H NMR (400 MHz, CDCl3) d: 7.57 (s,
1H), 7.36 (m, 3H), 7.28 (m, 2H), 5.52 (s, 2H), 4.93 (m, 2H),
4.18 (m, 4H), 3.53 (s, 1H), 3.48 (m, 1H), 3.27 (m, 1H), 1.50
(s, 3H), 1.42 (s, 3H), 1.34 (s, 3H), 1.30 (s, 3H); 13C NMR
(100 MHz, CDCl3) d: 145.89, 134.67, 129.09, 129.09, 128.74,
128.74, 128.17, 128.17, 109.69, 109.69, 81.58, 79.83, 78.91,
78.91, 76.56, 76.51, 65.52, 59.86, 54.21, 27.80, 27.72, 25.29,
25.29; HR-ESIMS m/z calcd for C23H31N3O6 [M+ H]
+
446.2221, found 446.2286.
4.1.4.42. 3-O-Methyl-4-[1-{(benzyl)-1H-1,2,3-triazol-4yl}
methoxy]-D-chiro-inositol 21a. Colorless liquid; Yield: 49%;
1H NMR (400 MHz, CDCl3) d: 7.61 (s, 1H), 7.37 (m, 3H),
7.30 (m, 2H), 5.54 (s, 2H), 4.85 (m, 2H), 4.17 (m, 4H), 3.53
(s, 1H), 3.44 (m, 1H), 3.30 (m, 1H); HR-ESIMS m/z calcd
for C17H23N3O6 [M+ H]
+ 366.1595, found 366.1617.
4.1.4.43. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(2-
cyanophenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-inositol
22. Yellowish liquid; Yield: 89%; 1H NMR (400 MHz, CDCl3)
d: 8.35 (s, 1H), 7.86 (m, 3H), 7.63 (m, 1H), 5.09 (m, 2H), 4.29
(m, 2H), 4.23 (s, 2H), 3.62 (s, 3H), 3.58 (m, 1H), 3.33 (m, 1H),
1.52 (s, 3H), 1.49 (s, 3H), 1.35 (s, 6H); 13C NMR (100 MHz,
CDCl3) d: 146.69, 138.68, 134.39, 134.39, 129.46, 125.37,
123.15, 115.70, 109.88, 109.77, 106.48, 81.45, 79.94, 79.02,
78.88, 76.64, 76.53, 65.12, 60.09, 27.82, 27.78, 25.32, 25.30;
HR-ESIMS m/z calcd for C23H28N4O6 [M+ H]
+ 457.2017,
found 457.2373.
4.1.4.44. 3-O-Methyl-4-[1-{(2-cyanophenyl)-1H-1,2,3-triazol-
4yl}methoxy]-D-chiro-inositol 22a. Yellowish liquid; Yield:
50%; 1H NMR (400 MHz, CDCl3) d: 8.33 (s, 1H), 7.83 (m,
3H), 7.64 (m, 1H), 5.09 (m, 2H), 4.39 (m, 2H), 4.27 (s, 2H),
3.61 (s, 3H), 3.57 (m, 1H), 3.35 (m, 1H); HR-ESIMS m/z calcd
for C17H20N4O6 [M+ H]
+ 377.1391, found 377.1429.
4.1.4.45. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(3-
cyanophenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-inositol
23. Yellowish liquid; Yield: 88%; 1H NMR (400 MHz, CDCl3)
d: 8.35 (m, 1H), 8.25 (s, 1H), 8.16 (m, 1H), 7.79 (m, 1H), 7.68
(t, J= 8.2 Hz, 1H), 5.08 (m, 2H), 4.25 (m, 4H), 3.63 (s, 3H),
3.59 (m, 1H), 3.37 (m, 1H), 1.55 (s, 3H), 1.53 (s, 3H), 1.34
(s, 6H); 13C NMR (100 MHz, CDCl3) d: 146.61, 147.10,
141.20, 125.51, 125.51, 120.55, 120.25, 120.25, 109.71, 109.73,
81.66, 79.87, 78.91, 78.83, 76.50, 76.43, 65.31, 59.93, 27.81,
27.77, 25.33, 25.33; HR-ESIMS m/z calcd for C23H28N4O6
[M+H]+ 457.2017, found 457.2375.d facile synthesis and bioevaluation of novel triazolyl analogs of D-(+)-pinitol.
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4yl}methoxy]-D-chiro-inositol 23a. Yellowish liquid; Yield:
48%; 1H NMR (400 MHz, CDCl3) d:
1H NMR (400 MHz,
CDCl3) d: 8.38 (m, 1H), 8.23 (s, 1H), 8.19 (m, 1H), 7.80 (m,
1H), 7.69 (t, J= 8.2 Hz, 1H), 5.09 (m, 2H), 4.27 (m, 4H),
3.64 (s, 3H), 3.60 (m, 1H), 3.37 (m, 1H); HR-ESIMS m/z calcd
for C17H20N4O6 [M+ H]
+ 377.1391, found 377.1431.
4.1.4.47. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(3-
nitrophenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-inositol 24.
Yellowish liquid; Yield: 88%; 1H NMR (400 MHz, CDCl3)
d: 8.59 (s, 1H), 8.30 (m, 1H), 8.27 (s, 1H), 8.20 (m, 1H), 7.76
(t, J= 8.2 Hz, 1H), 5.09 (m, 2H), 4.24 (m, 4H), 3.63 (s, 3H),
3.54 (m, 1H), 3.35 (m, 1H), 1.53 (s, 3H), 1.49 (s, 3H), 1.37,
(s, 3H), 1.36 (s, 3H); 13C NMR (100 MHz, CDCl3) d: 148.98,
137.88, 131.01, 125.82, 123.08, 120.59, 120.59, 115.01, 109.82,
109.78, 81.78, 79.96, 79.02, 78.87, 76.61, 76.54, 65.44, 59.92,
27.82, 27.76, 25.31, 25.31; HR-ESIMS m/z calcd for
C22H28N4O8 [M+H]
+ 477.1915, found 477.2006.
4.1.4.48. 3-O-Methyl-4-[1-{(3-nitrophenyl)-1H-1,2,3-triazol-
4yl}methoxy]-D-chiro-inositol 24a. Yellowish liquid; Yield:
48%; 1H NMR (400 MHz, CDCl3) d: 8.60 (s, 1H), 8.32 (m,
1H), 8.29 (s, 1H), 8.19 (m, 1H), 7.77 (t, J= 8.2 Hz, 1H),
5.09 (m, 2H), 4.33 (m, 4H), 3.60 (s, 3H), 3.55 (m, 1H), 3.33
(m, 1H); HR-ESIMS m/z calcd for C16H20N4O8 [M+H]
+
397.1289, found 397.1337.
4.1.4.49. 3-O-Methyl-1,2:5,6-bis-O-isopropylidene-4-[1-{(4-
nitrophenyl)-1H-1,2,3-triazol-4yl}methoxy]-D-chiro-inositol 25.
Yellowish liquid; Yield: 95%; 1H NMR (400 MHz, CDCl3)
d: 8.42 (d, J= 9.06 Hz, 2H), 8.25 (s, 1H), 7.98 (d,
J= 9.06 Hz, 2H), 5.09 (m, 2H), 4.26 (m, 4H), 3.63 (s, 3H),
3.54 (m, 1H), 3.33 (m, 1H), 1.53 (s, 3H), 1.47 (s, 3H), 1.36
(s, 6H); 13C NMR (100 MHz, CDCl3) d: 147.61, 147.12,
141.24, 125.58, 125.58, 120.56, 120.30, 120.30, 109.77, 109.77,
81.67, 79.86, 78.94, 78.83, 76.53, 76.44, 65.31, 59.95, 27.81,
27.76, 25.30, 25.30; HR-ESIMS m/z calcd for C22H28N4O8
[M+H]+ 477.1915, found 477.2012.
4.1.4.50. 3-O-Methyl-4-[1-{(4-nitrophenyl)-1H-1,2,3-triazol-
4yl}methoxy]-D-chiro-inositol 25a. Yellowish liquid; Yield:
55%; 1H NMR (400 MHz, CDCl3) d: 8.43 (d, J= 9.0 Hz,
2H), 8.27 (s, 1H), 7.99 (d, J= 9.0 Hz, 2H), 5.08 (m, 2H),
4.29 (m, 4H), 3.62 (s, 3H), 3.55 (m, 1H), 3.30 (m, 1H); HR-
ESIMS m/z calcd for C16H20N4O8 [M+ H]
+ 397.1289, found
397.1339.
4.2. Biology
All the human cancer cell lines (HL-60, HCT 116 and Mia-
Paca-2) were obtained from National Center for Cell Science,
Ganeshkhind, Pune-4111007 (India), and National Cancer
Institute, Biological Testing Branch DTP/DCTD/NCI, Fred-
erick Cancer Research and Development Center, Fairview
Center, Suite 205, 1003 West 7th Street, Frederick, MD
21701-8527 (USA). Sweet almond b-glucosidase and p-
nitrophenyl b-D-glucopyranoside for glycosidase inhibition
studies were purchased from Sigma. RPMI-1640 medium,
Penicillin, streptomycin, fetal calf serum, sodium bicarbonate,
phosphate buffer saline, trypsin, gentamycin sulphate, trypan
blue, ethanol, DMSO, and paraformaldehyde were purchasedPlease cite this article in press as: Shakeel-u-Rehman, et al., Click chemistry inspire
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scientific, PBS and trichloroactetic acid (TCA) from Merck
specialties private limited.
4.2.1. MTT cytotoxicity assay
All the compounds were evaluated against a panel of three
different human cancer cell lines viz. promyelocytic leukemia
(HL-60), colorectal carcinoma (HCT 116) and pancreatic
carcinoma (Mia-Paca-2) using MTT assay in a 96 well plate.
Cells were routinely maintained in RPMI 1640 (Sigma
Aldrich) supplemented with 10% FBS (Merck) and 1%
penicillin G and streptomycin (Sigma Aldrich) at 37 C in a
humidified incubator with 5% CO2 and were subcultured at
1:5 ratio once a week. For antiproliferative activity, com-
pounds were dissolved in cell culture grade DMSO. Briefly,
cells (104 cells/well) were cultured in 96 well tissue culture
plates and treated with different concentrations of compounds
for 48 h. At the end of incubation, 20 lL of MTT (2.5 mg/mL)
was added to the wells and incubated for 4 h. Absorbance was
recorded at 570 nm using Eliza Plate Reader. Inhibition of for-
mation of colored MTT formazan was taken as an index of
cytotoxicity activity. The IC50 values on the cancer cells of
different tissue origin used for screening were determined by
nonlinear regression analysis using graph pad software
(Chashoo et al., 2011).
4.2.2. b-D-glycosidase inhibitory assay
All buffers and solutions were prepared using Millipore filtered
water. Assays were performed in triplicate at 37 C using 96
well microtitre plates with a final assay volume of 300 ll.
All assays used 200 lL of 250 lM p-nitrophenyl glycoside
(substrate) solution, 50 ll test inhibitor solution and 50 lL
enzyme solution (0.2 U/mL), buffered to pH 5.0 in 0.12 M
phosphate (Pi) buffer. The liberated p-nitrophenol (PNP)
was measured at 405 nm after quenching the reactions with
100 lL borate buffer (pH 9.8, 0.2 M). Reaction mixture
containing Pi buffer (pH 5.0) in place of inhibitory samples
was used as negative control and castanospermine (1,6,7,
8-tetrahydroxyoctahydroindolizine), a commercially available
b-D-glycosidase inhibitor was included in the assay as positive
control. The percentage inhibition was calculated using the
following formula:
Inhibition ð%Þ ¼ 1ABSsample ABSpositive control
ABSnegative control
 100
For the time-scale inhibition studies, at each pre-incubation
time-step enzyme (50 ll of 0.2 U/mL) was added to the test
inhibitor (50 ll of 1000 lM) or Pi buffer for the negative con-
trol (50 ll). At the end of the pre-incubation time, the corre-
sponding p-nitrophenyl glycopyranoside (200 ll of 250 lM)
was added to each well and incubated for further 5 min at
37 C. To determine the inhibitory concentrations for the
various inhibitors, enzyme (50 ll of 0.2 U/mL) was added to
each well containing 50 ll of various concentrations of inhibi-
tor (0, 100, 250, 500, 1000, 1500 lM; to give final assay concen-
trations of 0, 16.6, 41.5, 83.3, 166.7 or 250.0 lM, respectively)
and pre-incubated for 1 h. After this time, the corresponding p-
nitrophenyl glycopyranoside was added (200 lL of 250 lM)
and incubated for a further 5 min. The results are expressed
as percentage activity relative to the control wells. The IC50
values were determined using graph pad prism 5 software.d facile synthesis and bioevaluation of novel triazolyl analogs of D-(+)-pinitol.
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